Instil Bio, INC. 8-K Filing
Ticker: TIL · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001789769
| Field | Detail |
|---|---|
| Company | Instil Bio, INC. (TIL) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Instil Bio, INC. (ticker: TIL) to the SEC on Mar 27, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.000001 (nge on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market).
How long is this filing?
Instil Bio, INC.'s 8-K filing is 2 pages with approximately 542 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2026-03-27 07:00:38
Key Financial Figures
- $0.000001 — nge on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market
Filing Documents
- til-20260327.htm (8-K) — 34KB
- q4-2025earningspressrelease.htm (EX-99.1) — 84KB
- image.jpg (GRAPHIC) — 3KB
- 0001789769-26-000018.txt ( ) — 247KB
- til-20260327.xsd (EX-101.SCH) — 2KB
- til-20260327_lab.xml (EX-101.LAB) — 22KB
- til-20260327_pre.xml (EX-101.PRE) — 13KB
- til-20260327_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 27, 2026, Instil Bio, Inc. (the "Company") issued a press release providing a corporate update and announcing its financial results for the fourth quarter and full year ended December 31, 2025, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated March 27, 2026. 104 The cover page of this report has been formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Dated: March 27, 2026 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)